Prosight Management, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001617201

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 36 positions · Total reported value $580.35M · Top-10 concentration 70.7% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 75.6% · 9 new · 12 cut · 13 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -1.1% · vs SPY -3.2% · Prev Value $580.35M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -6.1% · vs SPY -8.3% · Latest Value $515.48M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Prosight Management, LP disclosed 36 equity positions with a combined reported value of $580.35M. The filing implies a focused portfolio: its ten largest positions account for 70.7% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were LKFT ($61.26M), JANX ($58.44M), NKTR ($56.55M). By sector, the heaviest allocations are Health Care 83.6%, Technology 3.2%. Versus the prior quarter, allocation shifted toward Other (+1.7pp), Technology (+0.8pp) and away from Health Care (-0.8pp), Consumer Discretionary (-1.7pp).

Versus the prior quarter, Prosight Management, LP opened 9 new positions, trimmed 12 and fully exited 13, a turnover rate of 75.6% of positions. The portfolio's overlap with the prior quarter was 61% of names.

The largest new positions opened in Q2 2026 were INSM ($40.05M), MLYS ($12.14M), OPCH ($5.68M).

Of the 13 positions fully exited versus the prior quarter, the largest were CON ($10.85M), TERN ($10.67M), PHR ($9.22M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • INSM INSMED INC · $40.05M
  • MLYS MINERALYS THERAPEUTICS INC · $12.14M
  • OPCH OPTION CARE HEALTH INC · $5.68M
  • PFE PFIZER INC · $3.26M
  • EFOR EVERFORTH INC · $1.21M

Fully Exited (vs previous quarter)

  • CON CONCENTRA GROUP HOLDINGS PAR · prev qtr: $10.85M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $10.67M
  • PHR PHREESIA INC · prev qtr: $9.22M
  • SDGR SCHRODINGER INC · prev qtr: $5.80M
  • ROIV ROIVANT SCIENCES LTD · prev qtr: $4.99M
  • IMVT IMMUNOVANT INC · prev qtr: $4.37M
  • UPB UPSTREAM BIO INC · prev qtr: $2.17M
  • OMER OMEROS CORP · prev qtr: $1.85M

Insider Transactions (Form 4)

Latest Prosight Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Prosight Management, LP is an SEC-registered 13F filer based in Dallas, TX, United States. As of Q2 2026 it reported 36 US equity positions with a combined value of $580.35M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: DALLAS, TX, United States
  • SEC registration: 801-108047 (status: Approved), registered 2016-07-01
  • Regulatory AUM (Form ADV): $1.04B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds
  • Website: prosightcapital.com

Portfolio Structure

  • 36 positions · $580.35M reported value (Q2 2026)
  • Top 10 holdings = 70.7% of reported value
  • Largest position: LKFT (LAKEFRONT BIOTHERAPEUTICS NV) at 10.6%
  • Average position size: $16.12M

Sector Tilt

  • Health Care 83.6%
  • Information Technology 3.2%
  • (classified holdings cover 87% of value)

Quarterly Activity

  • Q2 2026: 5 new, 16 added, 15 reduced, 15 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Prosight Management, LP's rebalancing in Q2 2026 suggests a proactive approach to healthcare investments, with a focus on biotechnology and pharmaceutical companies. The addition of new positions and significant increases in existing holdings indicates a bullish outlook on the healthcare sector, particularly biotech and pharmaceuticals. 2. Key Moves: - Added: Lakefront Biophtherapeutics (LKFT), Janux Therapeutics (JANX), Nektar Therapeutics (NKTR), Boston Scientific (BSX), Shattuck Labs (STTK), Insmed (INSM), Alnylam Pharmaceuticals (ALNY), Syndax Pharmaceuticals (SNDX). - Reduced: Alkermes (ALKS), Kura Oncology (KURA). - Significant Changes: Lakefront Biophtherapeutics (LKFT) saw a 31.8% increase in shares, while Boston Scientific (BSX) and Shattuck Labs (STTK) saw increases of 59.7% and 19.1%, respectively. 3. Portfolio Structure: - Passive/Active: The fund appears to be actively managed, as evidenced by the significant changes in positions and the addition of new companies. - Sector Bias: The portfolio is heavily biased towards the healthcare sector, with a particular focus on biotechnology and pharmaceuticals. - Risk Appetite: The addition of new positions and significant increases in existing ones suggest a moderate to high risk appetite, as these sectors can be volatile. 4. Per-Holding One-Liner: - LKFT: Lakefront Biophtherapeutics NV (Biotechnology) - JANX: Janux Therapeutics Inc (Biotechnology) - NKTR: Nektar Therapeutics (Biotechnology) - BSX: Boston Scientific Corp (Medical Devices) - STTK: Shattuck Labs Inc (Biotechnology) - INSM: Insmed Inc (Medical Devices) - ALNY: Alnylam Pharmaceuticals Inc (Biotechnology) - SNDX: Syndax Pharmaceuticals Inc (Biotechnology) - KURA: Kura Oncology Inc (Biotechnology) - ALKS: Alkermes PLC (Biotechnology) - unverified 5. One-Sentence Style Summary: Prosight Management, LP's Q2 2026 rebalancing reflects a strategic bet on the healthcare sector, particularly biotechnology and pharmaceuticals, with a focus on active management and a moderate risk appetite.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 83.6%
Technology 3.2%
Other 13.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.04M $61.26M 10.56%
10.56%
Add
2 3.80M $58.44M 10.07%
10.07%
Add
3 810.00K $56.55M 9.74%
9.74%
Add
4 1.27M $54.22M 9.34%
9.34%
Add
5 5.96M $41.35M 7.12%
7.12%
Add
6 375.61K $40.05M 6.90%
6.90%
New
7 98.08K $29.53M 5.09%
5.09%
Add
8 1.20M $26.23M 4.52%
4.52%
Add
9 2.02M $22.18M 3.82%
3.82%
Reduce
10 394.39K $20.66M 3.56%
3.56%
Reduce
11 165.50K $19.69M 3.39%
3.39%
Add
12 106.20K $18.85M 3.25%
3.25%
Add
13 674.43K $17.63M 3.04%
3.04%
Add
14 107.39K $14.31M 2.47%
2.47%
Add
15 374.67K $14.02M 2.42%
2.42%
Add
16 449.80K $12.14M 2.09%
2.09%
New
17 7.82M $8.37M 1.44%
1.44%
Reduce
18 51.00K $7.48M 1.29%
1.29%
Add
19 17.00K $6.76M 1.17%
1.17%
Add
20 650.00K $6.10M 1.05%
1.05%
Reduce
21 268.27K $6.06M 1.04%
1.04%
Reduce
22 85.50K $5.87M 1.01%
1.01%
Reduce
23 270.72K $5.68M 0.98%
0.98%
New
24 978.99K $4.46M 0.77%
0.77%
Reduce
25 459.95K $3.85M 0.66%
0.66%
Reduce
26 135.37K $3.26M 0.56%
0.56%
New
27 157.50K $3.01M 0.52%
0.52%
Reduce
28 700.00K $2.39M 0.41%
0.41%
Add
29 474.64K $2.30M 0.40%
0.40%
Reduce
30 1.37M $1.56M 0.27%
0.27%
Reduce
31 39.73K $1.37M 0.23%
0.23%
Reduce
32 90.00K $1.22M 0.21%
0.21%
Reduce
33 67.50K $1.21M 0.21%
0.21%
New
34 1.10M $1.14M 0.20%
0.20%
Add
35 170.00K $994.50K 0.17%
0.17%
Reduce
36 36.86K $183.94K 0.03%
0.03%
Reduce

FAQ

What did Prosight Management, LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Prosight Management, LP reported 36 equity positions worth $580.35M in aggregate; its largest disclosed positions were LKFT ($61.26M), JANX ($58.44M), NKTR ($56.55M).

How large is Prosight Management, LP's portfolio?

Prosight Management, LP reported $580.35M of long equity holdings across 36 positions as of 2026-Q2. Top-10 holdings account for 70.7% of reported value.

What is Prosight Management, LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/prosight-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →